Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

MYECO GROUP LTD Share Issue/Capital Change 2009

Aug 2, 2009

65304_rns_2009-08-02_fe92e395-c8a8-4c83-8a3d-539f075a6858.pdf

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

==> picture [593 x 96] intentionally omitted <==

==> picture [593 x 96] intentionally omitted <==

TO: COMPANY ANNOUNCEMENTS OFFICE ASX LIMITED

DATE: 3 AUGUST 2009

ISSUE OF SHARES TO EMPLOYEES

Following approval by shareholders at their general meeting on 7[th] July 2009, the issue and allotment of 6,700,000 ordinary shares to the following employees of the Company will take place on 4[th] August 2009.

Dr Frank Glatz
Alex Fernando
Martin Kapsa
James Beck
6,000,000
300,000
200,000
200,000
6,700,000

The approved issue of 800,000 shares to Markus Leufgens will not take place.

An Appendix 3B applying for quotation of the new securities is attached.

John Wilson Company Secretary

==> picture [593 x 68] intentionally omitted <==

Appendix 3B

New issue announcement

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003.

Name of entity

Cardia Bioplastics Limited

ABN

89 064 755 237

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1
+Class of +securities issued or to be
issued
2
Number of +securities issued or to
be issued (if known) or maximum
number which may be issued
3
Principal terms of the
+securities
(eg, if options, exercise price and
expiry
date;
if
partly
paid
+securities, the amount outstanding
and
due
dates
for
payment;
if
+convertible
securities,
the
conversion
price
and
dates
for
conversion)
Ordinary Shares
6,700,000
Fully paid Ordinary Shares

1

Appendix 3B

New issue announcement

4
Do the +securities rank equally in all
respects from the date of allotment
with an existing
+class of quoted
+securities?
If the additional securities do not
rank equally, please state:
the date from which they do
the
extent
to
which
they
participate for the next dividend,
(in
the
case
of
a
trust,
distribution) or interest payment
the extent to which they do not
rank
equally,
other
than
in
relation to the next dividend,
distribution or interest payment
5
Issue price or consideration
6
Purpose of the issue
(If issued as consideration for the
acquisition of assets, clearly identify
those assets)
7
Dates of entering +securities into
uncertificated holdings or despatch
of certificates
8
Number
and
+class
of
all
+securities
quoted
on
ASX
(including the securities in clause
2 if applicable)
9
Number
and
+class
of
all
+securities not quoted on ASX
(including the securities in clause
2 if applicable)
Yes Yes
6,000,000 (2.5 Cents),700,000 (5 Cents)
Issued by way of remuneration and salary
sacrifice to the Managing Director and 3
employees of the Company.
4 August 2009
Number +Class
622,836,591 Ordinary Shares
Number +Class
NIL

2

Appendix 3B

New issue announcement

10
Dividend policy (in the case of a
trust, distribution policy) on the
increased capital (interests)
The
Board
of
Directors
will
consider
establishing
a
Dividend
policy
upon
achievement of profitable operations

Part 2 - Bonus issue or pro rata issue

11
Is
security
holder
approval
required?
12
Is the issue renounceable or non-
renounceable?
13
Ratio in which the +securities will
be offered
14
+Class of +securities to which the
offer relates
15
+Record
date
to
determine
entitlements
16
Will holdings on different registers
(or subregisters) be aggregated for
calculating entitlements?
17
Policy for deciding entitlements in
relation to fractions
18
Names of countries in which the
entity has
+security holders who
will
not
be
sent
new
issue
documents
Note: Security holders must be told how their
entitlements are to be dealt with.
Cross reference: rule 7.7.
19
Closing
date
for
receipt
of
acceptances or renunciations
20
Names of any underwriters
21
Amount of any underwriting fee or
commission
22
Names of any brokers to the issue
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

3

Appendix 3B

New issue announcement

23
Fee or commission payable to the
broker to the issue
24
Amount
of
any
handling
fee
payable
to
brokers
who
lodge
acceptances
or
renunciations
on
behalf of +security holders
25
If
the
issue
is
contingent
on
+security holders’ approval, the date
of the meeting
26
Date entitlement and acceptance
form and prospectus or Product
Disclosure Statement will be sent to
persons entitled
27
If the entity has issued options, and
the terms entitle option holders to
participate on exercise, the date on
which notices will be sent to option
holders
28
Date rights trading will begin (if
applicable)
29
Date rights trading will end (if
applicable)
30
How do +security holders sell their
entitlements
in
full
through
a
broker?
31
How do +security holders sell part
of
their
entitlements
through
a
broker and accept for the balance?
32
How do +security holders dispose
of their entitlements (except by sale
through a broker)?
33
+Despatch date
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

4

Appendix 3B New issue announcement

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

  • 34 Type of securities

( tick one )

  • (a)  Securities described in Part 1

  • (b)  All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

  • 35 If the[+] securities are[+] equity securities, the names of the 20 largest holders of the additional[+] securities, and the number and percentage of additional[+] securities held by those holders

  • 36 If the[+] securities are[+] equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over

  • 37 A copy of any trust deed for the additional[+] securities

6

Appendix 3B New issue announcement

Entities that have ticked box 34(b)

38 Number of securities for which +quotation is sought 39 Class of +securities for which quotation is sought

  • 40 Do the[+] securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?

If the additional securities do not rank equally, please state:

  • the date from which they do

  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

  • 41 Reason for request for quotation now

  • Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another security, clearly identify that other security)

  • 42 Number and[+] class of all[+] securities quoted on ASX ( including the securities in clause 38)

7

Appendix 3B New issue announcement

Quotation agreement

  • 1 +Quotation of our additional +securities is in ASX’s absolute discretion. ASX may quote the[+] securities on any conditions it decides.

  • 2 We warrant the following to ASX.

  • The issue of the[+] securities to be quoted complies with the law and is not for an illegal purpose.

  • There is no reason why those +securities should not be granted +quotation.

  • An offer of the[+] securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C (6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

  • Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any[+] securities to be quoted and that no-one has any right to return any[+] securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.

  • We warrant that if confirmation is required under section 1017F of the Corporations Act in relation to the[+] securities to be quoted, it has been provided at the time that we request that the[+] securities be quoted.

  • If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the[+] securities be quoted.

  • 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

  • 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Print name: John Wilson Date: 3/8/2009 Company Secretary

8